Empowering informed choices

 

Genetic Health

Advancing Breakthroughs with Genomic Solutions in Genetic Health

Illumina technology is pioneering genetic disease research, helping to advance breakthroughs in genetic health. With the significant impact of genetic disease and rare disease conditions on individuals of all ages and families worldwide, our focus is to develop solutions to facilitate early detection and intervention. This can help improve outcomes, promotes enduring good health, and raises awareness about the importance of one’s genetic health.

Inherited genetic disorders affect more people than you may realize. Currently they collectively account for about 1 in 5 infant mortalities and approximately 18% of pediatric hospital admissions1 and an underlying genetic cause can be identified in up to 15–20% of children with developmental delay.2 For adults, 25% of sudden cardiac arrest is due to an inherited genetic condition.3,4 Our next-generation sequencing (NGS) and microarray technologies can help genetic disease researchers identify causative genetic variants and chromosomal aberrations, and may enable early discovery.

Rare and Undiagnosed Disease Research

NGS technology can help genetic disease researchers discover causative variants associated with rare disorders.

Learn More

TruSight One

A targeted NGS gene panel for genetic disease research, including 4813 genes associated with rare diseases.

Learn More
Human CytoSNP-12 and CytoSNP-850k

Cytogenetic microarrays for genetic disease research on developmental delay and various other disorders. Designed to detect chromosomal aberrations associated with complex phenotypes.

Learn More
Medical Genome Initiative

This consortium of leading institutions is working to expand access to clinical whole genome sequencing (cWGS) for the diagnosis of genetic disease.

Learn More
“Arrays such as the CytoSNP-850K BeadChip have enabled us to discover phenotype links in a high fraction of samples and have been of huge advantage in research, leading to an explosion in our knowledge about the genetic basis of cancer and other diseases.” – Dr. Trilochan Sahoo

Featured Genetic Disease Research Articles

Infants with Undiagnosed Disease
NGS Identifies Rare Disease Variants in Infants with Undiagnosed Disease

Landmark NGS study leads to a national clinical diagnostic exome sequencing platform in Singapore.

Read Article
Scaling from Exome to WGS
Scaling from Exome to Whole-Genome Sequencing

The DRAGEN platform enables GeneDx to scale to whole-genome analysis and identify variants with precision.

Read Article
Progress for Patients with Rare and Undiagnosed Genetic Diseases
Progress for Patients with Rare and Undiagnosed Genetic Diseases

The Blue Cross Blue Shield Association (BCBSA) technology review organization, known as Evidence Street®, issues review supporting whole-genome sequencing.

Read Article

Inherited Disease Research

Illumina offers targeted sequencing research panels and cystic fibrosis testing for inherited diseases.
TruSight Inherited Diseases

A targeted gene panel for genetic disease research, including 552 genes associated with genotypes related to severe recessive childhood onset diseases.

Learn More
TruSight Cardio

A targeted gene panel for genetic disease research, including 174 genes associated with 17 inherited cardiac conditions.

Learn More
Cystic Fibrosis Testing

The most comprehensive commercially available panels for detection of causative and clinically relevant variants for cystic fibrosis.

Learn More
The Story of Tree Baby
The Story of Tree Baby

One Mother’s Quest for a Diagnosis

Read Article
A Genetic Data Matchmaking Service for Researchers
A Genetic Data Matchmaking Service for Researchers

Sano Genetics protects individual genetic information ownership while connecting people to meaningful research.

Read Interview
The Diagnostic Odyssey
The Diagnostic Odyssey

Every Diagnosis Matters

Read Article
References
  1. Kingsmore S. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. PLoS Curr. 2012; e4f9877ab8ffa9.
  2. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010: 86(5): 749-764.
  3. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation. 2012;125(4):620-637.
  4. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace. 2001;13(8):1077-1109.